Evidence map›Paper›PMID 41700598›Full record

ArticleThe Cochrane database of systematic reviews2026

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

Anneloes Noordhof, Oke Dimas Asmara, Kim de Jong, Rolof Gp Gijtenbeek, Ymkje Ma Huitema, Femke Hm van Vollenhoven, Ben Jw Venmans, Lizza Hendriks, Wouter H van Geffen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anneloes NoordhofDepartment of Pulmonary Diseases, Frisius MC, Leeuwarden, Netherlands.
Oke Dimas AsmaraDepartment of Pulmonary Diseases, Radboud UMC, Nijmegen, Netherlands.
Kim de JongDepartment of Epidemiology, Frisius MC, Leeuwarden, Netherlands.
Rolof Gp GijtenbeekDepartment of Pulmonary Diseases, Frisius MC, Leeuwarden, Netherlands.
Ymkje Ma HuitemaFrisius MC Academy, Knowledge and Information Center, Frisius MC, Leeuwarden, Netherlands.
Femke Hm van VollenhovenDepartment of Pulmonary Diseases, Frisius MC, Leeuwarden, Netherlands.
Ben Jw VenmansDepartment of Pulmonary Diseases, Frisius MC, Leeuwarden, Netherlands.
Lizza HendriksDepartment of Respiratory Medicine, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, Netherlands.
Wouter H van GeffenDepartment of Pulmonary Diseases, Radboud UMC, Nijmegen, Netherlands.ORCID 0000-0002-5976-0974

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the benefits and harms of G12C-inhibitors compared to chemotherapy in second line and beyond in adults with advanced/metastatic non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma (KRAS) G12C mutation.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungGenes, rasLung NeoplasmsMutationProto-Oncogene Proteinsras ProteinsHumansProto-Oncogene Proteins p21(ras)Randomized Controlled Trials as TopicSystematic Reviews as TopicAntineoplastic AgentsKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

PMID41700598
PMCPMC12910670

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.